第五届中华医学事务年会 全球变局 医学赋能 1

Transcription

1 第五届中华医学事务年会 全球变局 医学赋能 1

2 全新升级 New Upgrade 规模升级 形式升级 内容升级 中国 亚太, 乃至全球规模最大的 MA 行业盛会 增加国际论坛 ( 邀请欧美 亚太医学专家及医学事务负责人在线加盟 ),CMAC 全面与国际接轨, 传递中国医学事务最强音 新政下医学事务发展趋势最新研判 : 医学支持准入 \ 新产品上市 \ Patient Affairs 以专题方式进行更深入 理论 + 案例 相结合研讨 : 承接以往四届广覆盖传递医学事务职能和理念, 本届年会话题设置将全面改版 多视角, 全方位审视 医学回归 : 邀请更多企业跨部门负责人 专家学者 政府官员加盟, 全社会共建 共享医学驱动健康生态 Scale Upgrade Form Upgrade Content Upgrade The Largest Event of MA Industry in China, Asia-Pacific Region and Even the World. Add International Forum (Invite European and American, Asia-Pacific Medical Experts and Heads of Medical Affairs to Join Online), and CMAC Will be Fully in Line with International Standards, Delivering the Strongest Voice of China's Medical Affairs. New Research and Judgment on the Development Trend of Medical Affairs Under the New Policy: Medical Support Access, New Product Launch, Patient Affairs. In-Depth Discussion on "Theory+Case" in a Thematic Way: To Carry on the Function and Concept of Medical Affairs in the Past Four Annual Meetings, the Topic Setting of This Annual Meeting Will be Comprehensively Revised. From Multiple Perspectives, Comprehensively Examine "Medical Regression": Invite More Heads of Enterprises, Experts, Scholars, and Government Officials to Join in, and the Whole Society Will Build Together and Share the Health Ecology Driven by Medical. 更多亮点 将有三本新书呈现给医学事务行业同仁们 ( 医学事务优秀案例荟萃 中 英文, 上市后临床研究规范 ) 联合全球知名咨询公司德勤发布 2020 年中国医学事务基线调研全新报告 对医学事务行业发展有深远影响的多个项目和白皮书将启动或发布! 将举行 CMAC 五周年系列庆典活动 More Highlights Three New Books Will be Presented to Colleagues in the Medical Affairs Industry ("Collection of Outstanding Cases in Medical Affairs "in Chinese and English," Post-Marketing Clinical Research Specifications "). Released with Deloitte, a World-Renowned Consulting Company, "New Report on China s Medical Affairs Baseline Survey in 2020". A Number of Projects and White Papers Will be Initiated or Released that Will have a Profound Impact on the Development of the Medical Affairs Industry. The Fifth Anniversary of CMAC Will be Celebrated. 2 第五届中华医学事务年会 全球变局医学赋能

3 分论坛 Ⅰ Sub-Forum Ⅰ 医学联络官 : 从临床洞见到医学策略 (7 月 15 日下午 ) Medical Science Liaison (MSL): From Insight To Medical Strategy 张虹中国区医学和临床研发总监皮尔法伯制药 Helena ZHANG, Country Medical Director and Clinical Development Head, Pierre Fabre Pharmaceuticals 芮清医学事务执行总监安斯泰来制药 Qing RUI, Medical Affairs Executive Director, Astellas Pharmaceuticals 13:30-14:00 医学联络官商业敏锐度 MSL s Business Acumen 尹慧秋心血管治疗领域及基层医疗医学部负责人赛诺菲制药 Anna YIN, Head of CV & PC Medical Affairs, Sanofi 14:00-14:30 基于患者诊疗路径 (Patient Journey) 医学需求分析 Patient Journey and Medical Demand Analysis 雷燕肺癌与恶黑医学领域负责人诺华肿瘤 Yan LEI, TA Medical Affairs Head of Lung Cancer and Malignant, Novartis Oncology 14:30-15:00 如何挖掘高质量临床洞见 How to Generate High Quality Clinical Insights 任爱华医学事务总监西安杨森 Aihua REN, Medical Affairs Director, Xi'an Janssen 15:00-15:20 茶歇 Tea Break 15:20-15:50 数字医学精准获取洞见 Digital Medicine Generate Insights on Precise Way 李鹏医学联络官负责人益普生 Peng LI, MSL Head, Ipsen 15:50-16:20 从临床洞见到医学策略 From Insight to Medical Strategy 李萌心血管医学事务负责人默克中国医药健康 Meng LI, TA Head of Cardiovascular, Merck Healthcare China 16:20-16:45 医学联络官科学影响力 MSL Scientific Influence 徐冰医学联络官总监安斯泰来制药 Andy XU, MSL Director, Astellas 16:45-17:10 医学联络官在围新产品上市期医学价值实践与思考 MSL Practice and Perspective of in New Product Launches: The Value and Impact 谢鹂消化领域医学事务负责人武田制药 Li XIE, TA Medical Affairs Head of GI, Takeda Pharmaceutical 17:10-17:30 区域医学工作的挑战和突破实践与探索 Challenges and Breakthroughs in Regional Medical Practice and Exploration 王春燕医学经理辉瑞生物 Chunyan WANG, Medical Advisor Manager, Pfizer Biopharmaceuticals Group 17:30-18:00 圆桌论坛主持人 : 张虹芮清嘉宾 : 尹慧秋雷燕任爱华李鹏李萌徐冰谢鹂王春燕顾振东容梅 Panel Discussion Host: Helena ZHANG, Qing RUI Guest: Anna YIN, Yan LEI, Aihua REN, Peng LI, Meng LI, Andy XU, Li XIE Chunyan WANG, Jason GU, Mei RONG 第五届中华医学事务年会 全球变局医学赋能 3

4 分论坛 Ⅱ Sub-Forum Ⅱ 医学信息 : 变 赢未来 (7 月 15 日下午 ) Medical Information: Changes Wins The Future 王旭晖医学信息总监辉瑞制药 Xuhui WANG, Medical Information Director, Pfizer pharmaceuticals 乔丽云医学信息副总监默沙东 Joanna QIAO, Medical Information Associate Director, MSD 13:30-13:50 国内外医学信息发展现状 Domestic and Foreign Developmen of Medical Information 王旭晖医学信息总监辉瑞制药 Xuhui WANG, Medical Information Director, Pfizer Pharmaceuticals 13:50-14:10 多元业务下的 MI 价值探索 MI Value Exploration Under Multi Business 伏雨医学信息负责人益普生 Yu FU, Head of Medical Information, Ipsen 14:10-14:35 大环境下的 MI 转型方向和价值体现 MI Transformation Direction and Value Embodiment Under the General Environment 孟萌医学沟通经理上海罗氏 Meng MENG, Medical Communication Manager, Roche 14:35-15:00 从学术文献大数据中挖掘医学知识的方法 Mining Medical Knowledge Method from Big Data of Academic Literature 杜建健康医疗大数据研究中心北大医学部 JIan DU, Health Care Big Data Research Center, Peking University Medical Department 15:00-15:25 不同合作伙伴 MI 的多元化价值体现 MI Diversified Value Embodiment for Different Business Partners 陈静雅医学信息经理默沙东 Jingya CHEN, Medical Information Manager,MSD 15:25-15:40 茶歇 Tea Break 15:40-16:00 数字化助力 MI 职能高效开展 Digitalization Helps MI to Implement Functions Efficiently 周俊产品总监火石数智 Jun ZHOU, Product Director, AIMed 16:00-16:20 医学信息以患者为中心的案例分享 Patient-Centered Cases of Medical Information Sharing 谈澍医学信息副总监辉瑞制药 Shu TAN, Medical Information Associate Director, Pfizer Pharmaceutical 16:20-16:40 探索医学信息新视野 - 竞争信息分析 Exploring The New Vision of Medical Information-Competitive Information Analysis 刘旺医学信息经理西安杨森 Wang LIU, Medical Information Manager, Xi'an Janssen 16:40-17:00 主动识别企业内部的医学信息需求 Proactively Identify Medical Information Needs in the Company 秦阿妮高级医学信息经理默克中国医药健康 Anne QIN, Senior Medical Information Manager, Merck Healthcare, China 17:00-17:20 学术会议线上直播 : 为更多的医生提供便捷有效的第一手医学信息 Academic Conference Live Webcast: Providing Convenient and Effective First-Hand Medical Information to More Doctors 王凯玲医学信息和医学教育经理阿斯利康 Kailing WANG, Medical Information and Medical Education Manager, Astrazeneca 17:20-18:00 圆桌论坛 Panel Discussion 主持人 : 王旭晖乔丽云嘉宾 : 伏雨孟萌杜建陈静雅谈澍刘旺秦阿妮王凯玲张婷艳 HOST: Xuhui WANG, Joanna QIAO Guests: Yu FU, Meng MENG, Jian DU, Jingya CHEN, Shu TAN, Wang LIU, Anne QIN Kailing WANG, Tingyan ZHANG 4 第五届中华医学事务年会 全球变局医学赋能

5 分论坛 Ⅲ Sub-Forum Ⅲ 器械专场 : 变局下, 医学助力新产品快速上市 (7 月 15 日下午 ) Medical Device Session: Medical Support New Product Launching Rapidly Under Changing Situation 崔太根医学总监 BD 公司 Andy CUI, Medical Director, BD 濮存莹医学科学事务部总监罗氏诊断 Vivien PU, Medical and Scientific Affairs Director, Roche Diagnostics 李婉医学事务总监强生医疗 Vivian LI, Medical Director, Johnson & Johnson 13:30-14:00 境外临床试验数据助推新产品上市的探索 Leveraging Overseas Clinical Trial Data to Support New Product Launch 史嘉惠临床开发副总监 BD 大中华区医学事务部 Jiahui SHI, Associate Director of Clinical Development, BD Greater China 14:00-14:30 综合运用临床证据满足中国临床评价要求 Chain of Clinical Evidenecs to Support China Registration 王烨临床研发负责人爱尔康亚洲临床研发部 Adam WANG, Head of Clinical Development, Clinical Department, Asia, Alcon 14:30-15:00 代理商模式下的医学事务 : 从后台走向前线 Medical Affairs in Agency Mode: From Backstage to Frontline 徐美林医学总监 GE 医疗 Meilin XU, Medical Director, GE Healthcare 15:00-15:20 茶歇 Tea Break 15:20-15:50 变局下,IVD 医学事务在新产品上市中的价值 The Value of IVD Medical Affairs in New Product Launching Under the Changing Situation 夏奕俊医学事务总监生物梅里埃 Yijun XIA, Medical Affairs Director, BioMerieux 15:50-16:20 通过跨部门合作实现医学事务的价值 Realize the Value of Medical Affairs in Cross-Departmental Cooperation 刘冉医学事务与专业教育总监奥森多医疗 Ran LIU, Medical Affairs & Pro Edu Director, Ortho Clinical Diagnostics 16:20-16:50 Lisa, 抓住机会 :Carpediem! - 从患者需求角度, 如何助力新产品在中国的上市 Lisa, Seize the Opportunity: Carpediem! - From the Perspective of Patient Demand, How to Promote the Launch of New Products in China 范虹医学事务总监美敦力医疗 Hong FAN, Medical Affairs Director, Medtronic 16:50-17:20 One Team - 深度融入产品研发, 加速产品上市 One Team - Deeply Integrate into Product Research and Development for NPI Acceleration 孙晓炜法规 医学 临床事务部高级总监飞利浦大中华区 Xiaowei SUN, Head of Regulatory, Medical&Clinical Affairs, Philips Greater China 17:20-18:00 圆桌论坛 : 变局下, 医学助力新产品快速上市主持人 : 崔太根濮存莹李婉嘉宾 : 史嘉惠王烨徐美林夏奕俊刘冉范虹孙晓炜田玲 Panel Discussion:Medical Support New Product Launching Rapidly Under Changing Situation Host: Host: Andy CUI, Vivien PU, Vivian LI Guest: Jiahui SHI, Adam WANG, Meilin XU, Yijun XIA, Ran LIU, Hong FAN, Xiaowei SUN, Ling TIAN 第五届中华医学事务年会 全球变局医学赋能 5

6 分论坛 Ⅳ Sub-Forum Ⅳ 药物警戒职能优化 : 体系化建设 (7 月 15 日上午 ) PV Responsibility Advancement: Systematic Establishment 张燕药物安全副总监礼来公司 Jenny ZHANG, Patient Safety Associate Director, Eli Lilly and Company 孙晓云科学策略 & 商业创新中心总经理四环医药集团 Xiaoyun SUN, General Manager of Scientific Strategy & Business Innovation Center 09:00-09:30 上市前以患者为中心药物警戒体系 Patient-Centered PV Systematic in Pre-launch 蓝丽丽药物警戒总监海思科 Coco LAN, Pharmacovigilance Director, Haisco Pharmaceutical Group 09:30-10:00 临床试验药物警戒的工作重点 Key Emphasis of PV Job During Clinical Trials 苏敏实药物警戒总监轩竹医药 Minshi SU, Pharmacovigilance Director, Xuanzhu Biopharma 10:00-10:30 上市后药物警戒体系建设的策略性考量 The Strategic Consideration of Establish PV System in Post-Marketing 李承霖药物警戒总监先声药业 Chenglin LI, Pharmacovigilance Director, Simcere Pharmaceutical 10:30-10:50 茶歇 Tea Break 10:50-11:20 药物警戒体系的国际化接轨之路 The Internationalization of PV System 邓剑雄学会副秘书长 & 主委广东省药理学会 & 广东省药物警戒联盟 Jianxiong DENG Associate Secretary General & Chairman Guangdong Pharmacology Society & Guangdong Pharmacovigilance Alliance 11:20-12:00 圆桌论坛 : 药物警戒职能优化 : 体系化建设主持人 : 张燕孙晓云嘉宾 : 蓝丽丽苏敏实邓建雄李承霖 Panel Discussion:PV Responsibility Advancement: Systematic Establishment Host: Jenny ZHANG, Xiaoyun SUN Guest: Coco LAN, Minshi SU, Jianxiong DENG, Chenglin LI 6 第五届中华医学事务年会 全球变局医学赋能

7 分论坛 Ⅳ 药物警戒职能优化 : 高效运行 (7 月 15 日下午 ) PV Responsibility Advancement: High-Effective Operation 杨晓燕药物警戒高级总监百济神州 Xiaoyan YANG, Senior Pharmacovigilance Director, BeiGene 祝捷全球药物警戒副总裁绿叶制药 Jie ZHU, Vice President, Global Pharmacovigilance, Luye Pharma Group Ltd. 13:30-14:05 药物警戒与欧美接轨还需要多久? When PV in China Will Be Able to Meet the Western Practice? 祝捷全球药物警戒副总裁绿叶制药 Jie ZHU, Vice President, Global Pharmacovigilance, Luye Pharma Group Ltd. 14:05-14:40 创新产品药物警戒职能由运营到科学决策 Pharmacovigilance of Innovation Product: From Operation to Scientific Decisions 杨晓燕药物警戒高级总监百济神州 Xiaoyan YANG, Senior Pharmacovigilance Director, BeiGene 14:40-15:15 以药物安全为中心跨部门高效合作 Cross Functional Collaboration in Pharmacovigilance 毕微药物警戒负责人益普生制药 Wei BI, Pharmacovigilance Head, Ipsen 15:15-15:35 茶歇 Tea Break 15:35-16:10 基于药物警戒数据的风险管理及价值挖掘 Risk Management and Value Proposition from the Data in Pharmacovigilance 张翾跨业务领域药品安全负责人强生医疗 Chery ZHANG, Pharmacovigilance Head of Cross TA, Johnson & Johnson 16:10-16:45 高绩效药物警戒团队建立 Building High Performance Team in Pharmacovigilance 初晓玉药物警戒总监艾迈医疗 Xiaoyu CHU, Pharmacovigilance Director, AffaMed 16:45-17:30 圆桌论坛 : 药物警戒职能优化 : 高效运行主持人 : 杨晓燕祝捷嘉宾 : 毕微张翾初晓玉 Panel Discussion:PV Responsibility Advancement: High-Effective Operation Host: Lynn ZHOU, Jie ZHU Guest: Wei BI, Chery ZHANG, Xiaoyu CHU 第五届中华医学事务年会 全球变局医学赋能 7

8 分论坛 Ⅴ Sub-Forum Ⅴ 临床研究 : 以患者为中心临床研究 (7 月 15 日上午 ) Clinical Trial: Patient-Centered Clinical Trial 党焱医学总监雅培营养品北亚区 Yan DANG, Medical Director, Abbott Nutrition North Asia 张善中医学本部, 副统括住友制药 ( 苏州 ) 有限公司 Shanzhong ZHANG, Medical Division, Deputy Head, Sumitomo Pharmaceutical (suzhou) Ltd. Co. 08:40-09:00 以患者为中心研究设计考量因素 Considerations of Patient-Centered Study Design 姚晨统计室主任 & 副所长北京大学第一医院 & 北京大学临床研究所 Chen YAO, Statistics Office Director & Associate Director Peking University First Hospital & Peking University Clinical Research Institute 09:00-09:20 上市后临床研究 : 从将就到规范 Post-Marketing Studies: From Ordinary to Standardization 张莹医学事务总监第一三共 Amber ZHANG, Medical Affairs Director, Daiichi Sankyo Co. 09:20-09:40 提升患者体验助力高质量临床证据生成 High Quality Evidence Generating by Improvement of Patient Experience 冯蕾心血管和内科中央医学负责人施维雅制药 Lei FENG, CV and IM central Medical Head, Servier 09:40-10:00 基于患者报告结局 (PRO) 构建新型临床研究评价体系 Construct a New Clinical Trial Evaluation System Based on PRO 郭子姮肿瘤治疗领域医学事务负责人武田制药 Ziheng GUO, Head of Oncology Medical Affairs, Takeda Pharmaceutical 10:00-10:20 茶歇 Tea Break 10:20-10:40 患者洞察与高质量临床研究 Patient Insight and Qualified Clinical Trial 崔敏医学事务负责人益普生多元健康事业部 Annie CUI, Head of Medical Affairs, Ipsen Consumer Health Care 10:40-11:00 临床研究策略与指南 共识 The Strategy, Guidelines and Consensus of Clinical Trial 谢抒医学事务总监意大利凯西 Lyra XIE, Medical Affairs Director, Chiesi Pharmaceutical 11:00-11:20 系统评价在临床研究中的应用和价值 The Application and Value of Systematic Evaluation in Clinical Research 赵赛循证医学顾问 SRS Sai ZHAO, Systematic Review Solutions Ltd Evidence-based Medicine Consultant Visiting Lecturer 11:20-12:00 圆桌论坛 : 以患者为中心临床研究主持人 : 党焱张善中嘉宾 : 姚晨张莹冯蕾郭子姮崔敏谢抒赵赛赵娜 Panel Discussion:Patient-Centered Clinical Trial Host: Yan DANG, Shanzhong ZHANG Guest: Chen YAO, Amber ZHANG, Lei FENG, Ziheng GUO, Annie CUI, Lyra XIE Sai ZHAO, Na ZHAO 新书发布会 New Book Release 张云副总经理 & 中央医学事务负责人江苏恒瑞 Joanna ZHANG, Deputy General Manager, Head of Central Medical Affairs, Heng Rui Pharmaceutical 12:00-12:30 上市后临床研究规范 - 中华医学事务行业共识篇 Norms of Post-Marketing Studies- Chinese Medical Affairs Industry Consensus 8 第五届中华医学事务年会 全球变局医学赋能

9 分论坛 Ⅴ Sub-Forum Ⅴ 临床研究 : 真实世界研究规范化新时代 (7 月 15 日下午 ) Clinical Trial: New Era of Real-World Study Standardization 马敬东高级医学事务总监灵北制药 Jingdong MA, Senior Medical Affairs Director, Lundbeck 林东虎临床开发 & 医学部部长大鹏药品 Donghu LIN, Clinical Development&Medical Dept Director, Taiho Pharmaceutical 13:30-13:55 真实世界研究助力新产品生命周期管理 Real World Study Supports the New Product Life Cycle Management 于淼高级医学总监费森尤斯卡比 Miao YU, Senior Medical Director, Fresenius Kabi 13:55-14:20 真实世界数据与治疗路径的探索 The Discovery of Real-World Data and Treatment Journey 张蕾医学事务总监辉瑞生物 Lei ZHANG, Medical Affairs Director, Pfizer Biopharmaceuticals Group 14:20-14:45 区域大数据平台支撑下的医药科研新模式 A New Model of Medical Research Supported by Regional Big Data Platform 李雪莉数据服务事业部总经理浪潮集团 Shirley LI, General Manager of Data Services Division, Inspur Group 14:45-15:10 让每个医药人建立 RWS 数据库的神兵利器 Let Every Medical Person Build the Magic Weapon of RWS Database 周洪创始人德派软件 HongZHOU, Founder, DAP Software 15:10-15:35 真实世界研究中影响数据质量考量因素与应对策略 The Affective Considerations of Data Quality and Its Countermeasures in Real World Study 马悦医学沟通与真实世界研究负责人默克中国医药健康 Lydia MA, Head of Medical Communication&RWE, Merck Healthcare China 15:35-15:55 茶歇 Tea Break 15:55-16:20 从智能分析模型构建谈目标导向型 RWS 新模式 Objective Oriented RWS from the Perspective of Intelligent Analysis Model Construction 姜学卿 MedAI 事业部副总裁百奥知 Jason JIANG, MedAI Vice President, Bioknow 16:20-16:45 真实世界临床研究的伦理审查关键要素 Key Considerations and Elements of Ethic Review in Real World Study 李丹丹医学博士中国人民解放军总医院 (301) Dandan LI, MD, PLA General Hospital 16:45-17:10 医疗大数据用于支持监管决策的注意事项 Considerations for Using Medical Big Data to Support Regulatory Decision-Making 刘述森首席医学证据官, 真实世界研究院院长神州医疗 Shusen LIU, Chief Medical Evidence Officer, Dean of The Real World Study Institute Digital China Health 17:10-17:35 临床数据库价值挖掘 Value Generation of Clinical Database 商红岩生物统计和真实世界证据副总监阿斯利康制药 Hongyan SHANG, Biometrics and RWE Associate Director, AstraZeneca 17:35-18:20 圆桌论坛 : 真实世界研究规范化未来主持人 : 马敬东林东虎嘉宾 : 于淼张蕾李雪莉周洪马悦姜学卿李丹丹刘述森商红岩 Panel Discussion: The Future of Real World Study Standardization Host: Jingdong MA, Donghu LIN Guest: Miao YU, Lei ZHANG, Shirley LI, HongZHOU, Lydia MA, Jason JIANG, Dandan LI Shusen LIU, Hongyan SHANG 第五届中华医学事务年会 全球变局医学赋能 9

10 分论坛 Ⅵ Sub-Forum Ⅵ 疫苗医学事务 : 疫苗新政 下的应对策略 (7 月 15 日下午 ) Vaccine Medical Affairs: The Countermeasures Under The New Policy of Vaccine 杨俊峰疫苗医学事务总监辉瑞生物制药集团 Junfeng YANG, Director of Vaccine Medicine, Pfizer Biopharmaceuticals Group 曹峻洋副总裁首席医学官辉瑞生物制药集团 Felix CAO, Vice President, Chief Medical Officer, Pfizer Biopharmaceuticals Group 13:30-14:00 疫苗新政对上市后研究的影响 The Impact of New Vaccine Policy on Post Market Research 王华庆免疫首席专家中国疾控中心 Huaqing WANG, Chief Expert of Immunization, China CDC 14:00-14:30 未确认 Unconfirmed 徐爱强副主任山东省疾控中心 Aiqiang XU, Deputy Director, Shandong CDC 14:30-15:00 疫苗政策新政解读 Introduction to Vaccine Policy 李卫东准入总监辉瑞生物制药集团 Weidong LI, Market Access Director, Pfizer Biopharmaceuticals Group 15:00-15:30 疫苗政策对医学事务的影响 The Impact of Vaccine Policy on Medical Affairs 杨俊峰疫苗医学事务总监辉瑞生物制药集团 Junfeng YANG, Director of Vaccine Medicine, Pfizer Biopharmaceuticals Group 15:30-15:50 茶歇 Tea Break 15:50-16:30 圆桌论坛 : 疫苗新政 下的应对策略 Panel Discussion: Strategies Under the New Vaccine Policy 10 第五届中华医学事务年会 全球变局医学赋能

11 分论坛 Ⅶ Sub-Forum Ⅶ 药物经济学 : 价值医疗与科学决策 (7 月 15 日下午 ) HEOR: Value-Based Medicine and Scientific Decision-Making 董鹏卫生经济与结果研究总监辉瑞生物制药集团 Peng DONG, HEOR Director, Pfizer Biopharmaceuticals Group 曹海俊卫生经济及健康结果研究总监礼来医学部 Haijun CAO, HEOR Director Medical Department, Eli Lilly and Company 13:30-14:00 药物经济学在医保谈判中的作用和未来的趋势 HEOR in Health Care Negotiation and its Future Trend 吴晶教授天津大学 Jing WU, Professor, Tianjin University 14:00-14:30 医学事务的 Senior Leader 怎么看待 HEOR 的发展 How Senior Leaders of Medical Affairs think about the Development of HEOR 王莉药物研发及医学事务高级副总裁礼来公司 Li WANG, Senior Vice President, Drug Development & Medical Affairs, Eli Lilly and Company 14:30-15:00 HEOR 怎么和其他部门合作 Ⅰ How HEOR Cooperates with Other Departments Ⅰ 栾鸾高级卫生经济与结果研究经理辉瑞生物制药集团 Ying LUAN, Sr HEOR Manager, Pfizer Biopharmaceuticals Group 15:00-15:30 HEOR 怎么和其他部门合作 Ⅱ How HEOR Cooperates with Other Departments Ⅱ 张岩磊高级卫生经济和真实世界研究经理 Yanlei ZHANG, Sr Research Scientist, Eli Lilly and Company 15:30-15:50 茶歇 Tea Break 15:50-16:30 圆桌论坛 : 不同架构下的 HEOR 部门优势 Panel Discussion: HEOR Departments Advantages under Different Structures 第五届中华医学事务年会 全球变局医学赋能 11

12 分论坛 Ⅷ Sub-Forum Ⅷ 医学卓越和能力提升 (7 月 15 日下午 ) Medical Excellence and Capability Enhancement 孙静医学卓越总监 GSK Jing SUN, Medical Excellence Director, GSK 万巍医学卓越负责人安进中国 Viola WAN, Head of Medically Capability and Operations, Amgen China 13:30-14:00 敏捷转型中的医学卓越 Medical Excellence in Agile Transformation 韩丹丹高级医学合规与卓越经理上海罗氏 Dandan HAN, Senior Medical Compliance and Excellence Manager, Roche 14:00-14:30 医学事务部胜任力模型的制定与评估 Medical Competency Model: Development and Assessment 孙维怿医学卓越高级专员西安杨森 Weiyi SUN, Senior Medical Excellence Specialist, Xi'an Janssen 14:30-15:00 建立符合医学事务部门特点培训体系 Building Training System for Medical Affairs 葛晓医学运营和卓越负责人赛诺菲制药 Xiao GE, Head of Medical Operations, Sanofi 15:00-15:20 茶歇 Tea Break 15:20-15:50 主题培训提升医学事务能力 Elevate Medical Affairs Ability Through Subject Learning 梁立平医学出版与医学事务培训副总监默沙东 Louie LIANG, Medical Publication And Medical Affairs Learning Associate Director, MSD China 15:50-16:20 变局下 MSL 人才培养策略 The MSL Talent Development Strategy Under Unprecedented Changes 李大汉 MSL 卓越负责人赛诺菲制药 Teddy LI, Head of MSL Excellence, Sanofi 16:20-16:50 医学顾问非职权领导力 The Non-Authority Leadership of MA 吴汉军医学能力负责人礼来公司 Hanjun WU, Head of Medical Capability Eli Lilly and Company 16:50-17:30 圆桌论坛 : 打造适合医学人才发展培养体系主持人 : 孙静万巍嘉宾 : 韩丹丹孙维怿葛晓梁立平李大汉吴汉军 Panel Discussion:Building Training System Suitable for the Development of Medical Talents Host: Jing SUN, Viola WAN Guest: Dandan HAN, Weiyi SUN, Xiao GE, Louie LIANG, Teddy LI, Hanjun WU 12 第五届中华医学事务年会 全球变局医学赋能

13 全球变局医学赋能 Global Change, Medical Empowerment(7 月 16 日上午 ) 王莉药物研发及医学事务高级副总裁礼来公司 Li WANG, Senior Vice President, Drug Development & Medical Affairs, Eli Lilly and Company 贺李镜高级副总裁 & 首席医学官和记黄埔医药 James HE, Senior Vice President & CMO, Hutchison Whampoa 08:20-08:30 开幕致辞 Opening Speech 谷成明副总裁 & 医学事务负责人赛诺菲中国及新兴市场中国区 Chengming GU, Vice President&Head of Medical Affairs, Sanofi China&Emerging Markets China 毛京梅副总裁 & 医学事务负责人默克中国医药健康 Vivian Mao, Vice President & Head of Medical Affairs, Merck Healthcare, China 08:30-08:50 行业领袖期望 : 医学事务商业新引擎 The Expectation of Industry Leaders: New Business Mode of Medical Affairs 罗杰仁董事总经理 & 副主席默克中国医药健康 &RDPAC Rogier Janssens, Managing Director and General Manager, Merck Healthcare, China &Vice Chairman, RDPAC 08:50-09:10 行业领袖期望 : 医学领导力与企业创新发展 The Expectation of Industry Leaders: Medical Leadership and Innovation Development of Enterprise 单国洪总裁武田中国 Sean SHAN, President, Takeda China 09:10-09:30 医学赋能新商业模式 Medical Empowering New Business Model 谷成明副总裁 & 医学事务负责人赛诺菲中国及新兴市场中国区 Chengming GU, Vice President&Head of Medical Affairs, Sanofi China&Emerging Markets China 09:30-09:50 变局下医学人定位与发展 Medical Practitioners Positioning and Development under Changing Situation 毛京梅副总裁 & 医学事务负责人默克中国医药健康 Vivian MAO, Vice President &Head of Medical Affairs, Merck Healthcare, China 09:50-10:10 茶歇 Tea Break 疫情下数字化创新论坛 Digital Innovation Forum in Pandemic Situation (7 月 16 日上午 ) 康志清阿斯利康高级顾问 & 高管教练, 原阿斯利康副总裁 & 医学事务负责人 Iris KANG, Senior Consultant&Executive Coach, Former Vice President&Head of Medical Affairs, Astrazeneca 郑以漫医学副总裁默沙东 Yiman ZHENG, Vice President, Head of China Medical Affairs, MSD 10:10-10:30 中国医学事务 2020 数字化趋势洞察 Insight into China Medical Affairs Digital Trend in 2020 皮婷婷合伙人德勤中国 Tingting PI, Partner, Deloitte China 10:30-10:50 智见未来 - 智能医学机器人的机遇与挑战 Future is Coming: Opportunities and Challenges for Intelligent Medical Robots 杨红飞火石创造 & 火石数智创始人 Hongfei YANG, Founder of Firestone & AIMed 10:50-11:10 携手同行, 促进中国 RWE 产业繁荣发展 Work Together to Promote Use of Real-World Evidence in China 郝一鸣创新医疗解决方案事业部总经理开心生活 Yiming HAO, General Manager of Innovative Healthcare Solutions, HLT 11:10-12:00 圆桌论坛 : 疫情下, 数字化医学如何做? Panel Discussion : How to do Digital Medical in Pandemic Situation 主持人 : 康志清郑以漫嘉宾 : 王莉贺李镜谷成明毛京梅王芸 (RDPAC 科学与药政事务高级总监 ) KAZI AHMED( 已邀请, 利奥制药 ) 皮婷婷杨红飞郝一鸣 Host:Iris KANG, Yiman ZHENG Guests:Li WANG, James HE, Chengming GU, Vivian MAO, Sara WANG KAZI AHMED(Invited, LEO Pharma)Tingting PI, Hongfei YANG, Yiming HAO 第五届中华医学事务年会 全球变局医学赋能 13

14 医学引领新产品快速上市 (7 月 16 日下午 ) Medical Leading A New Product To Launch 李玮医学部副总裁上海罗氏 Joyce LI, Country Medical Director, Roche 陈杰医学事务负责人武田制药 Jie CHEN, Head of Medical Affairs, Takeda China 13:00-13:20 打造完整强证据链助力新产品成功上市 Build Whole Strong Evidence Chain to Ensure New Product Launch Successfully 李玮医学部副总裁上海罗氏 Joyce LI, Country Medical Director, Roche 13:20-13:40 新产品上市 窗口期 医学策略 Medical Strategy for New Product Launch During WindowPeriod 曹娴血液肿瘤医学部负责人西安杨森 Xian CAO, Head of Hematology Medical Affairs, Xi'an Janssen 13:40-14:00 医学联络官在新产品上市期战略性布局 Strategic Distribution for MSL During Product Launch 崔楠糖尿病医学部 & 医学合规负责人赛诺菲制药 Nancy CUI, Head of Diabetes Medical Affairs & Medical Compliance, Sanofi 14:00-14:20 策略 计划与执行 : 如何使用真实世界证据支持卓越上市 RWE Enabled Launch Excellence 谢洋大中华区真实世界研究负责人 IQVIA Yang Xie, Head of Real-World Solutions, IQVIA Greater China 14:20-14:40 数字化创新平台助力新产品上市 Digital Innovation Platform Supports New Product Launch 林勍翃首席医学官安进中国 Helen LIN, Chief Medical Officer, Amgen China 14:40-15:00 变局下, 数字化临床研究解决方案 Digital Clinical Trial Solution Under Changing Situation 彭逸天联合创始人药研社 Yitian PENG, Cofounder, Yaoyanshe 15:00-15:30 圆桌论坛 : 围新产品上市期医学价值最大化主持人 : 李玮陈杰嘉宾 : 曹娴崔楠谢洋林勍翃彭逸天诸思赟 ( 百时美施贵宝创新药疾病领域负责人 ) 王春花 ( 吉利德肝炎领域高级医学总监 ) Panel Discussion:Maximize the Medical Value of New Product Launch Host: Joyce LI, Jie CHEN Guest: Xian CAO, Nancy CUI, Yang Xie, Helen LIN, YitianPENG Siyun ZHU(Head of Innovative Medicine and Disease, BMS ) Susan WANG(Senior Medical Director, Hepatitis area, Gilead China) 15:30-15:50 茶歇 Tea Break 14 第五届中华医学事务年会 全球变局医学赋能

15 真实世界证据支持研发和监管决策 (7 月 16 日下午 ) Supporting R&D And Regulatory Decision-Making By RWE 童玉医学事务负责人诺华肿瘤 Jade TONG, Head of China Medical Affairs, Novartis Oncology 迟海东首席医学官礼来公司 Haidong CHI, CMO, Eli Lilly and Company 15:50-16:10 使用真实世界证据支持药物研发和监管决策 Supporting R&D and Regulatory Decision-Making by RWE 陈平雁教授 & 主任委员南方医科大学生物统计学系 & 中华预防医学会生物统计分会 Pingyan CHEN, Professor & Chairman of Committee Department of Biostatistics, Southern Medical University & Chinese Preventive Medicine Association Biometric Society 16:10-16:30 如何利用真实世界研究挖掘数据价值 How to Use Real World Study to Generate Valuable Data 孙鑫循证医学研究中心主任四川大学华西临床医学院 Xin SUN, Head of Chinese Cochrane Center West China School of Medicine in Sichuan University 16:30-16:50 真实世界研究中的研究设计与统计分析计划 Protocol Design and Statistical Analysis Plan in Real World Study 张发宝博士, 董事长梅斯医学 Dr. Paul ZHANG, Board Chairman, MedSci 16:50-17:10 人工智能和真实世界研究助力药物医学事务 Medical Affairs Empowered by AI & RWS 胡启曈首席技术官遥领医疗科技 Qitong Hu, CTO, Longleding Medical Technology 17:10-17:30 新冠疫情下真实世界研究的执行挑战和机遇 Implementation Challenges and Opportunities for Real World Research under COVID-19 Outbreaks 龙健晶博士, 高级医学总监太美医疗科技 Dr. Jianjing LONG, Senior Medical Director, Taimei Technology 17:30-18:30 圆桌论坛 : 真实世界数据到高质量真实世界证据主持人 : 童玉迟海东嘉宾 : 陈平雁孙鑫张发宝胡启瞳龙健晶 Panel Discussion: From RWD to High Quality RWE Host: Jade TONG, Haidong CHI Guest: Pingyan CHEN, Xin SUN, Paul ZHANG, Qitong HU, JianjinLONG 第五届中华医学事务年会学术盛典 & 颁奖典礼 (7 月 16 日晚上 ) The 5th Chinese Medical Affairs Conference Academic Grand Ceremony & Award Ceremony 郎志慧 ( 已邀请 ) 医学事务 & 药物警戒高级副总裁拜耳制药 Zhihui LANG(Invited, Medical & PV (China&HongKong) VP, Bayer 赵迪医学事务负责人诺和诺德 Di ZHAO, Head of Medical Affairs, Norva Nordisk 19:20-20:50 学术活动, 媒体采访, 颁奖等 Academic Activities, Interviews, Awards, Etc. 第五届中华医学事务年会 全球变局医学赋能 15

16 医学证据支持科学准入 (7 月 17 日上午 ) Medical Evidence Support Scientific Access 李滨副总裁医学事务负责人西安杨森 Kevin LI, Vice President, Head of Medical Affairs, Xi'an Janssen 周苏医学负责人益普生制药 Su ZHOU, Head of Medical, Ipsen 08:30-08:50 中国医药政策趋势解读 The Interpretation of Medicine Policy Tendency in China 宋瑞霖执行会长中国医药创新促进会 Ruilin SONG, Executive President PhlRDA (China Pharmaceutical Industry Research and Development Association) 08:50-09:10 药物经济学证据医学价值及未来趋势 The Medical Value and Future Tendency of HEOR 宣建伟医药经济研究所所长中山大学药学院 Jianwei XUAN, Director of Medicine Economic Research Institute School of Pharmaceutical Sciences, Sun Yat-Sen University 09:10-09:30 NRDL 医学证据沟通和谈判资料准备 NRDL Medical Evidence Communication and Negotiation Preparation 董鹏卫生经济与结果研究总监辉瑞生物制药集团 Peng DONG, HEOR Director, Pfizer Biopharmaceuticals Group 09:30-09:50 医生图谱助力 SE(Scientific Expert) 高效管理 Physician Graph Helps High-Efficiency Management for SE 卢文庆首席执行官脉络洞察 Wenqing LU, CEO, MeDomino Insights 09:50-10:10 社交聆听 & 画像图谱赋能精准医学数字化沟通 Social Listening and Academic Profiling in Precision Communication Based on Medical & Digital Empowerment 张新燕首席执行官惠每健康 Eva ZHANG, CEO, HUIMEI HEALTH 10:10-10:30 茶歇 Tea Break 16 第五届中华医学事务年会 全球变局医学赋能

17 从医学事务到患者事务 (7 月 17 日上午 ) From Medical Affairs To Patient Affairs 林勍翃首席医学官安进中国 Helen LIN, Chief Medical Officer, Amgen China 曹峻洋副总裁首席医学官辉瑞生物制药集团 Felix CAO, Vice President, Chief Medical Officer, Pfizer Biopharmaceuticals Group 10:30-10:50 音声相和前后相随 : 新业务环境下突出患者为中心 Why Working Together with Patients Will Enhance Our Success in China Pharmaceutical Industry 王斌辉中国医学部负责人施维雅制药 Barry WANG, Head of China Medical & Scientific Affairs, Servier 10:50-11:10 浅谈以患者为中心 - 从患者需求到企业落地实践 Talking About Patient-centered - From Patient Needs to Enterprise Implementation 徐旭峰患者支持与解决方案负责人赛诺菲制药 Doug XU, Head of Patient Solution Medical Affairs Department, Sanofi 11:10-11:30 患者需求洞察赋能政府和药企决策 The Insight of Patient Organization and Patient Needs- From Patients Perspective 黄如方创始人及主任蔻德罕见病中心 (CORD, 原罕见病发展中心 ) Rufang HUANG, Founder & Director Chinese Organization for Rare Disorders (CORD) 11:30-12:00 圆桌论坛 : 患者组织与多方对话主持人 : 林勍翃曹峻洋嘉宾 : 患者组织负责人黄如方史星翔 ( 全国银屑病患者组织的发起人 ) 顾洪飞 ( 淋巴瘤之家负责人 ) 关涛 ( 北京血友之家罕见病关爱中心理事长, 中国血友之家会长 ) 医学专家与药企王斌辉徐旭峰杨进刚 ( 副主任医师, 中国医学科学院阜外医院 ) 钟铮 ( 赛诺菲特药领域医学部负责人 ) Panel Discussion: Patient Organization with Multiparty Talks Host: Felix CAO, Su ZHOU Guest: Head of Patient Organization[Rufang HUANG, Xingxiang SHI (Founder of the National Organization for Psoriasis Patients), Hongfei GU (Lymphoma Patient Association), Tao GUAN (President,Hemophilia Home of China & President,Hemophilia Home of Beijing)] Medical Experts and Representatives of Pharmaceutical Companies [Barry WANG, Doug XU, Jingang YANG ( Associated Chief Physician, Fuwai Hospital, CAMS) Zheng ZHONG (Special Care Medical Head,Sanofi) 第五届中华医学事务年会 全球变局医学赋能 17

18 医学事务新战略定位 (7 月 17 日下午 ) New Strategic Positioning of Medical Affairs 吴铃首席科学官及医学事务部负责人诺华制药中国 Ling WU, Chief Scientific Officer&Head of Medical Affairs, Novartis 杨海英医学事务副总裁阿斯利康制药 Celine YANG, Vice President, Head of Medical Affairs, Astrazeneca 13:00-13:20 知识管家 - 医学事务新战略定位 Knowledge Steward -New Strategic Positioning of Medical Affairs 周苏医学负责人益普生制药 Su ZHOU, Head of Medical, Ipsen 13:20-13:40 颠覆传统, 跨界升级, 塑新定位, 履新征程 -AZ 医学事务部组织能力建设的思考 "Subversion of Tradition, Cross-Border Upgrading", Shaping New Positioning and Embarking on A New Journey-Reflections on The Organizational Capacity Building of AZ Medical Affairs Department 杨海英医学事务副总裁阿斯利康制药 Celine YANG, Vice President, Head of Medical Affairs, Astrazeneca 13:40-14:00 成功 MSL 的背后站着是什么? What Stands Behind a Successful MSL 李智医学事务团队负责人勃林格殷格翰 Zhi LI, Head of Medical Affairs, Boehringer Ingelheim 14:00-14:20 医学智库与商业敏感度 Medical Intelligence and Business Acumen 任婷婷普药及内分泌医学事务总监默克中国医药健康 Tingting REN, Head of GM&E Medical Affairs, Merck Healthcare China 14:20-14:40 医学能力模型与数字化 Medical Competency Model and Digitization 贾鹏剑高级医学赋能经理百时美施贵宝 Pengjian JIA, Senior Medical Capability Manager, BMS 14:40-15:00 疫情下如何看待医学人未来职业发展 Career Development Under Changing Situation in Healthcare Industry 姚强医学事务与临床发展总监百特大中华区 Qiang YAO, Medical Director, Medical Affairs&Clinical Development, Baxter Greater China 15:00-16:00 圆桌论坛 : 疫情下, 医学人如何适应快速变化带来的不确定性主持人 : 吴铃杨海英嘉宾 : 赵迪 ( 诺和诺德医学事务负责人 ) 吴国平 ( 艾尔建医学事务总监 ) 陈淑颖 ( 雅培制药医学事务总监 ) 谢抒 ( 意大利凯西医学事务总监 ) 范俊豪 ( 珐博进医学事务总监 ) 孙晓东 ( 已邀请 )( 爱施健医学总监 ) 蒋峥嵘 ( 卫材制药医学部部长 ) 陈亮 ( 利洁时制药大中华区医学事务总监 ) 邵维良 ( 已邀请 )( 参天制药医学负责人 ) Panel Discussion: How Medical Practitioners Adapt to Uncertainty Along With Fast Changing Environment Host: Ling WU, Celine YANG Guest: Di ZHAO(Head of Medical Affairs, Norva Nordis)Robbin WU (Medical Affairs Director, Allergan) Susan CHEN(Medical Affairs Director, Abbott) Lyra XIE(Medical Affairs Director, Chiesi Pharmaceutical) Kurt FAN(Medical Affairs Director, Fibrogen) Xiaodong SUN(Medical Director, Aspen) Michael JIANG (Medical Head, Eisai China)Pony CHEN (Medical Affairs Director, Greater China, Reckitt Benckiser Pharmaceuticals) Weiliang SHAO (Head of Medical, Santen China) 新书发布会 New Book Launch Ceremony (7 月 17 日下午 ) 戢溥公共事务 & 医学事务副总裁萌蒂制药大中华区 Pu JI, Vice President, PA, PR&MA, Mundi Greater China 张莹医学事务总监第一三共 Amber ZHANG, Medical Affairs Director, Daiichi Sankyo 于淼高级医学总监费森尤斯卡比 Miao YU, Senior Medical Director, Fresenius Kabi 16:00-16:30 医学事务优秀案例荟萃 新书发布 ( 中英文 ) Collection of Best Practice in Medical Affairs New Book Release (Bilingual) 18 第五届中华医学事务年会 全球变局医学赋能

19 赞助商 Sponsorships 第五届中华医学事务年会 全球变局 医学赋能 19

20 注册费用 Registration Fee 研发制药公司 : 7 月 1 日前报名享受团体优惠如下 : 大会 + 会前研讨会价格 (1 人 )5500 元人民币 / 人大会 + 会前研讨会价格 (2-4 人 )5000 元人民币 / 人大会 + 会前研讨会价格 (5-9 人 )4500 元人民币 / 人大会 + 会前研讨会价格 (10 人以上 )3500 元人民币 / 人仅参加 7 月 15 日会前研讨会价格 800 元人民币 / 人 7 月 1 日后 : 大会 + 会前研讨会价格 6000 元人民币 / 人 非研发制药公司 : 大会 + 会前研讨会价格 (1 人 )8000 元人民币 / 人 仅参加 7 月 15 日会前研讨会价格 2000 元人民币 / 人 R&D pharmaceutical company: The group discount is as follows if you register before July 1: Conference + pre-conference forum price (1 person) RMB 5500 / person The price of conference + pre-conference forum (2-4 persons) is RMB 5000 / person The price of conference + pre-conference forum (5-9 persons) is 4500 RMB/person The price of conference + pre-conference forum (more than 10 people) is 3500 RMB/person The price is 800 RMB/person only for attending the pre-conference forum on July 15 If you register after 1 July: The price of conference + pre-conference forum is 6000 RMB/person Non-R&D pharmaceutical companies: The price of conference + pre-conference forum (1 person) is 8000 RMB/person The price of attending the pre-conference forum on July 15 is RMB 2000 /person only 20 第五届中华医学事务年会 全球变局医学赋能

21 第五届中华医学事务年会 全球变局医学赋能 21

22 22 第五届中华医学事务年会 全球变局医学赋能